Salesforce's 34% Stock Surge Faces Scrutiny Over Earnings Quality

What happened

Salesforce posted an earnings beat that sent the stock surging 34%, but the article from 24/7 Wall Street questions the source of the surprise, urging investors to look beyond the headline. The beat likely included significant acquisition contributions from Informatica, which the company itself disclosed contributed $444 million in Q1 and is expected to add about three points to FY27 growth, suggesting the underlying organic performance may be weaker than the market reaction implies. The existing DeepValue master report already rates the stock a WAIT, citing concerns about AI monetization quality, seat compression risk, and the need for clearer organic acceleration before paying a higher multiple. The article's caution aligns with these risks, reinforcing that the surge may be driven by over-enthusiasm rather than a fundamental shift in growth quality. Investors should await confirmation of current remaining performance obligation (cRPO) holding at or above 14% and organic subscription re-acceleration before considering the rally sustainable.

Implication

Investors should remain cautious despite the stock surge because the earnings beat appears to lean on acquisition-aided growth and possibly non-recurring items, which the market may be overestimating. The key risk remains that AI-related seat compression and consumption-based pricing could suppress organic growth, and the surge may not reflect durable value creation. Until Salesforce demonstrates that cRPO growth stays at 14% or higher and organic subscription revenue re-accelerates in the second half of fiscal 2027, the stock lacks a margin of safety at elevated levels. Existing holders should consider trimming above $195, while potential buyers should wait for a pullback toward $150 or evidence of clean organic acceleration. The article reinforces the existing WAIT rating, suggesting that patience is more prudent than chasing momentum.

Thesis delta

The new article does not alter the overall WAIT thesis; it adds a timely warning that the recent 34% surge may be based on low-quality earnings beats. The thesis remains that Salesforce must prove organic acceleration and sustainable AI monetization to justify higher valuations. The article's skepticism reinforces the existing focus on cRPO and organic subscription growth as critical checkpoints.